Publication

Poster | Real-World Evidence of Immune Checkpoint Inhibitor Treatment in Lung Cancer Patients from a Belgian Multicenter Study

Immune checkpoint inhibitors (ICIs) have shown survival benefits in multiple clinical trials in patients with lung cancer. To gain further insights into real-world treatment patterns of lung cancer patients treated with ICIs, we performed a multicenter study.

Download our poster, as presented at the European Lung Cancer Congress 2024, and discover the initial findings of the ICI-treated lung cancer patient cohort of 730+ patients regarding demographic and clinical characteristics, ICI treatments, and overall survival (OS).

Oncology

In this Publication you’ll learn:

In this article you’ll learn:

The preliminary results discussed demonstrate the feasibility of autonomously extracting and locally validating federated hospital databases—a crucial tool for accessing real-world data on patients with lung cancer receiving ICI treatment. Analyses focusing on immune-related adverse events, comorbidities, tumor stage, anatomical pathology, and treatment lines and histology are ongoing.

Complete the form above to download the poster and discover the methods used and the first results obtained.

Click HERE to visit our Lung Cancer Dataset Insights overview for more information on the LynxCare datasets within our European hospital network.

The preliminary results discussed demonstrate the feasibility of autonomously extracting and locally validating federated hospital databases—a crucial tool for accessing real-world data on patients with lung cancer receiving ICI treatment. Analyses focusing on immune-related adverse events, comorbidities, tumor stage, anatomical pathology, and treatment lines and histology are ongoing.

Complete the form above to download the poster and discover the methods used and the first results obtained.

Click HERE to visit our Lung Cancer Dataset Insights overview for more information on the LynxCare datasets within our European hospital network.

Publication

Poster | Real-World Evidence of Immune Checkpoint Inhibitor Treatment in Lung Cancer Patients from a Belgian Multicenter Study

Immune checkpoint inhibitors (ICIs) have shown survival benefits in multiple clinical trials in patients with lung cancer. To gain further insights into real-world treatment patterns of lung cancer patients treated with ICIs, we performed a multicenter study.

Download our poster, as presented at the European Lung Cancer Congress 2024, and discover the initial findings of the ICI-treated lung cancer patient cohort of 730+ patients regarding demographic and clinical characteristics, ICI treatments, and overall survival (OS).

DOWNLOAD
DOWNLOAD
Talk to an Expert

Discover the initial findings of the ICI-treated lung cancer patient cohort of 730+ patients regarding demographic and clinical characteristics, ICI treatments, and overall survival (OS).

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.